Matthew J. Ellis

1.0k total papers · 64.8k total citations
321 papers, 26.8k citations indexed

About

Matthew J. Ellis is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Matthew J. Ellis has authored 321 papers receiving a total of 26.8k indexed citations (citations by other indexed papers that have themselves been cited), including 185 papers in Oncology, 162 papers in Cancer Research and 102 papers in Genetics. Recurrent topics in Matthew J. Ellis's work include Breast Cancer Treatment Studies (115 papers), Estrogen and related hormone effects (91 papers) and HER2/EGFR in Cancer Research (83 papers). Matthew J. Ellis is often cited by papers focused on Breast Cancer Treatment Studies (115 papers), Estrogen and related hormone effects (91 papers) and HER2/EGFR in Cancer Research (83 papers). Matthew J. Ellis collaborates with scholars based in United States, Canada and United Kingdom. Matthew J. Ellis's co-authors include Charles M. Perou, Daniel F. Hayes, X. Cynthia, G. Thomas Budd, Michael Craig Miller, Gerald V. Doyle, Leon W.M.M. Terstappen, W. Jeffrey Allard, Jeri Matera and Massimo Cristofanilli and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Matthew J. Ellis

310 papers receiving 26.2k citations

Hit Papers

normalize citations (0→100%) normalize lifespan (0→100%) sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

2004 3.5k citations Massimo Cristofanilli, G. Thomas Budd et al. New England Journal of Medicine profile →
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

2009 3.1k citations Joel S. Parker, Michael E. Mullins et al. Journal of Clinical Oncology profile →
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

2009 1.6k citations Maggie C.U. Cheang, Stephen Chia et al. JNCI Journal of the National Cancer Institute profile →
CDK4/6 inhibition triggers anti-tumour immunity

2017 990 citations Shom Goel, Molly J. DeCristo et al. Nature profile →
Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

2006 807 citations Daniel F. Hayes, Massimo Cristofanilli et al. Clinical Cancer Research profile →
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

2001 791 citations Matthew J. Ellis, Andrew Coop et al. Journal of Clinical Oncology profile →
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

2012 600 citations Ron Bose, Shyam M. Kavuri et al. Cancer Discovery profile →
Long noncoding RNA MALAT1 suppresses breast cancer metastasis

2018 544 citations Jongchan Kim, Hai-long Piao et al. Nature Genetics profile →
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer

2010 540 citations Torsten O. Nielsen, Joel S. Parker et al. Clinical Cancer Research profile →
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

2001 529 citations W. Eiermann, Stefan Paepke et al. Annals of Oncology profile →
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

2005 505 citations Howard A. Burris, Herbert I. Hurwitz et al. Journal of Clinical Oncology profile →
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

2015 453 citations Sara M. Tolaney, William T. Barry et al. New England Journal of Medicine profile →
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

2016 380 citations J.F.R. Robertson, Igor Bondarenko et al. The Lancet profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Matthew J. Ellis	15.9k	13.1k	9.0k	6.7k	4.7k	321	26.8k
Lisa A. Carey	16.0k 1.0×	12.1k 0.9×	7.2k 0.8×	5.3k 0.8×	3.1k 0.6×	418	25.8k
Fátima Cardoso	13.7k 0.9×	10.5k 0.8×	7.3k 0.8×	4.9k 0.7×	3.1k 0.7×	401	25.1k
John A. Foekens	11.4k 0.7×	10.6k 0.8×	13.5k 1.5×	3.6k 0.5×	3.3k 0.7×	337	25.5k
Lars A. Akslen	14.0k 0.9×	11.6k 0.9×	13.8k 1.5×	4.4k 0.7×	3.3k 0.7×	313	29.0k
Ana M. González-Angulo	15.1k 0.9×	11.3k 0.9×	8.9k 1.0×	5.1k 0.8×	2.6k 0.5×	281	25.1k
Jonas Bergh	15.6k 1.0×	11.6k 0.9×	11.1k 1.2×	4.9k 0.7×	3.3k 0.7×	521	29.0k
Edith A. Perez	20.7k 1.3×	11.1k 0.8×	6.6k 0.7×	5.8k 0.9×	4.4k 0.9×	400	30.0k
Charles Swanton	12.7k 0.8×	12.6k 1.0×	12.9k 1.4×	8.4k 1.3×	2.2k 0.5×	321	30.3k
George W. Sledge	14.7k 0.9×	9.5k 0.7×	7.5k 0.8×	6.3k 0.9×	1.7k 0.4×	442	25.3k
Vicente Valero	17.2k 1.1×	13.2k 1.0×	5.4k 0.6×	4.9k 0.7×	2.2k 0.5×	499	27.8k

Countries citing papers authored by Matthew J. Ellis

Since Specialization

Citations

This map shows the geographic impact of Matthew J. Ellis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew J. Ellis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew J. Ellis more than expected).

Fields of papers citing papers by Matthew J. Ellis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew J. Ellis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew J. Ellis. The network helps show where Matthew J. Ellis may publish in the future.

Co-authorship network of co-authors of Matthew J. Ellis

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew J. Ellis. A scholar is included among the top collaborators of Matthew J. Ellis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew J. Ellis. Matthew J. Ellis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact